Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Chemical Sympathectomy Following Peripheral Nerve Block With Liposomal Bupivacaine

Next Previous
Trial Profile

Chemical Sympathectomy Following Peripheral Nerve Block With Liposomal Bupivacaine

Status: Discontinued
Phase of Trial: Phase II/III

Latest Information Update: 23 May 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bupivacaine (Primary)
  • Indications Peripheral vascular disorders; Raynaud's disease; Scleroderma
  • Focus Pharmacodynamics

Most Recent Events

  • 21 Mar 2016 Planned End Date changed from 1 Dec 2016 to 1 Mar 2016, according to ClinicalTrials.gov record.
  • 21 Mar 2016 Planned primary completion date changed from 1 Dec 2016 to 1 Mar 2016, according to ClinicalTrials.gov record.
  • 21 Mar 2016 Status changed from recruiting to discontinued due the the PI leaving the institution, according to ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top